Could daratumumab induce the maturation of plasmablasts in Plasmablastic lymphoma?-Potential therapeutic applications

Eur J Haematol. 2021 Apr;106(4):589-592. doi: 10.1111/ejh.13584. Epub 2021 Feb 2.

Affiliations

¹ Hematology and Cellular Therapy Department, La Conception, University Hospital of Marseille, AP-HM, Marseille, France.
² Hematology and Vascular Biology Laboratory, La Conception, University Hospital of Marseille, AP-HM, Marseille, France.
³ Pharmacy Unit, La Conception,, University Hospital of Marseille, AP-HM, Marseille, France.
⁴ Department of Pathology, La Timone Hospital, AP-HM, Marseille, France.

PMID: 33469987
DOI: 10.1111/ejh.13584

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / pharmacology*
Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents, Immunological / pharmacology*
Antineoplastic Agents, Immunological / therapeutic use
Cell Differentiation / drug effects*
Humans
Molecular Targeted Therapy
Plasma Cells / drug effects*
Plasma Cells / pathology*
Plasmablastic Lymphoma / drug therapy
Plasmablastic Lymphoma / pathology*

Substances

Antibodies, Monoclonal
Antineoplastic Agents, Immunological
daratumumab